Cell Therapy CDMO Services & Engineered Cell Manufacturing Support

Cell therapy manufacturing turns living cells into controlled therapeutic products.

That makes the manufacturing model different from conventional biologics. The product is not only a molecule made by cells. The cell itself becomes the therapy, the delivery system, the functional unit, and the quality challenge. A cell therapy program must control identity, viability, phenotype, potency, purity, sterility, chain of custody, chain of identity, cryopreservation, logistics, and clinical-site readiness at the same time.

CDMO Network supports this work through a connected manufacturing and development model. Instead of forcing every program into one internal facility, one platform, or one narrow service menu, CDMO Network routes each program through the right combination of cell therapy specialists, GMP manufacturing capacity, vector and editing support, analytical partners, cryogenic logistics, quality systems, and regulatory CMC resources.

That matters because cell therapy is not one market. It is a group of very different manufacturing problems.

This modality group includes autologous cell therapies, allogeneic cell therapies, CAR-T, TCR-T, NK cell therapies, CAR-NK, iPSC-derived therapies, stem cell therapies, MSC products, dendritic cell therapies, macrophage cell therapies, hematopoietic cell therapies, tumor-infiltrating lymphocytes, Treg therapies, gamma delta T cells, engineered immune cells, ex vivo edited cells, reprogrammed cells, closed-system manufacturing, decentralized manufacturing, and point-of-care cell therapy models.

Each cell therapy type changes the CDMO route.

An autologous CAR-T program does not route like an allogeneic NK platform. An iPSC-derived product does not route like an MSC program. A TIL process does not route like a closed-system engineered cell workflow. A gene-modified cell product requires coordination between cells, vectors, editing materials, release methods, and cryopreservation. A point-of-care model requires a different operational design from centralized GMP manufacturing.

CDMO Network connects these requirements into one coordinated development and manufacturing path.

Our support includes process development, GMP manufacturing, viral vector coordination, genome editing material support, cell sourcing, donor strategy, activation, transduction, editing, expansion, washing, harvest, formulation, cryopreservation, analytical testing, potency assays, sterility coordination, mycoplasma testing, endotoxin testing, adventitious agent testing coordination, chain of identity, quality systems, regulatory CMC, tech transfer, cold chain, and clinical supply planning.

Because we operate as a network, we can combine capabilities that are rarely available together in one CDMO model. A single program can require CAR-T process development, vector input coordination, CRISPR material support, closed-system manufacturing, rapid sterility strategy, cryobag format review, post-thaw potency, clinical-site thaw instructions, chain-of-identity controls, and multi-region GMP transfer. Many CDMOs offer pieces of that. CDMO Network can coordinate the full route.

Cell therapy programs succeed when living product quality remains controlled from starting material through clinical use.

Why cell therapy requires a different CDMO model

Cell therapy grew from decades of work in transplantation, immunology, cancer biology, stem cell biology, and cell engineering.

Early hematopoietic stem cell and bone marrow procedures showed that cells could function as therapeutic products. Later advances in immune-cell biology, T-cell receptor science, viral vector delivery, gene editing, iPSC biology, and closed-system bioprocessing expanded the field into a major therapeutic category. The University of

Pennsylvania became closely associated with modern CAR-T development through work led by Carl June and colleagues, while iPSC biology traces heavily to Shinya Yamanaka’s 2006 reprogramming work at Kyoto University. Dana-Farber has also remained active in cellular immunotherapy, including TIL therapy, where patient tumor-infiltrating lymphocytes are removed, expanded outside the body, and infused back into the patient.

This history matters because cell therapy manufacturing did not grow from the same model as protein manufacturing.

A recombinant protein process can often focus on expression, purification, formulation, and fill-finish. A cell therapy process must preserve a living cell population through sourcing, handling, activation, modification, expansion, washing, formulation, freezing, shipment, thawing, and administration. The product can change if timing, media, activation conditions, vector exposure, passage number, cell density, cryopreservation method, thaw conditions, or handling procedures shift.

The CDMO route must protect biological state as well as product identity.

Cell therapy manufacturing is therefore part production process, part logistics system, part clinical coordination model, and part quality-control framework. A successful program does not only manufacture cells. It preserves the right cells in the right state for the right use.

CDMO Network is built around that reality. The network model allows a program to combine niche expertise across cell biology, process engineering, analytics, GMP production, cryogenic logistics, and regulatory strategy without treating those pieces as separate vendors working in isolation.

Autologous cell therapy manufacturing

Autologous cell therapy programs use patient-specific starting material.

That creates a manufacturing model where each batch can represent one patient. The process must handle variable starting material, narrow clinical timelines, individualized scheduling, chain of identity, chain of custody, rapid release, cryopreservation control, and clinical-site coordination.

CDMO Network supports autologous programs across leukapheresis material handling, receipt, selection, activation, transduction, editing where relevant, expansion, washing, formulation, cryopreservation, release testing, shipment, thawing coordination, and site-use planning.

Our support includes autologous CAR-T, TCR-T, TILs, dendritic cell therapies, macrophage therapies, gene-modified autologous cells, and personalized cell products.

Autologous manufacturing requires operational discipline. A process delay can affect patient scheduling. A labeling error can create serious risk. A release testing delay can affect treatment timing. A cold chain excursion can affect product usability. A poorly defined chain-of-identity process can damage the entire program.

The manufacturing route must keep the patient-linked product traceable, viable, functional, and usable through the full treatment path.

Examples include:

• CAR-T programs requiring leukapheresis coordination, T-cell activation, viral vector transduction, expansion, cryopreservation, release testing, and hospital-site thaw support.
• TCR-T programs requiring target-specific engineering, vector or editing material coordination, VCN testing, phenotype analysis, and potency development.
• TIL programs requiring tumor material processing, lymphocyte expansion, sterility strategy, rapid manufacturing logistics, and clinical timing control.
• Dendritic cell programs requiring differentiation, antigen loading, activation-state control, phenotype testing, and patient-specific scheduling.

In many autologous programs, the manufacturing challenge is not only whether cells can be expanded. The challenge is whether the process can produce a consistent patient-linked product despite biological variability, tight timelines, and release constraints.

Allogeneic cell therapy manufacturing

Allogeneic cell therapy programs use donor-derived, engineered, banked, or platform cell sources to create products that can serve multiple recipients.

These programs create different manufacturing requirements from autologous therapy. They need donor or source-cell control, banking strategy, expansion scale, batch consistency, comparability, cryopreservation, release testing, inventory management, and distribution planning.

CDMO Network supports allogeneic programs across cell banking, master and working cell bank support, donor material strategy, expansion process development, closed-system manufacturing, genetic modification where relevant, harvest, washing, formulation, cryopreservation, stability, QC testing, and commercial-readiness planning.

Allogeneic platforms can include NK cells, CAR-NK, iPSC-derived products, MSCs, T-cell products, gamma delta T cells, macrophage products, and engineered immune-cell platforms.

The central challenge is repeatability.

A batch must remain consistent across expansion, engineering, cryopreservation, storage, distribution, and clinical use. Scale-up must protect phenotype, potency, viability, and purity. Banking strategy must support product comparability and long-term supply.

CDMO Network can connect upstream cell source strategy, banking, GMP manufacturing, analytics, cryogenic storage, release testing, and distribution planning through one coordinated route. That is especially useful for programs that need both specialized biology support and platform-style operational planning.

Allogeneic programs require manufacturing systems that can operate like platforms while preserving cell-specific biology.

CAR-T, TCR-T, and engineered immune cells

Engineered immune cell therapies require coordination between cellular processing and genetic modification.

CAR-T and TCR-T programs typically require cell selection, activation, viral vector or nonviral modification, expansion, washing, formulation, cryopreservation, release testing, and clinical delivery planning. Related engineered immune-cell platforms can include CAR-NK, engineered Tregs, gamma delta T cells, macrophages, and other immune-cell formats.

CDMO Network supports engineered cell programs with cell process development, vector coordination, transduction strategy, editing material support, vector copy number support, phenotype testing, potency assays, viability testing, sterility coordination, mycoplasma testing, endotoxin testing, cryopreservation, quality systems, and regulatory CMC planning.

The vector or editing material is not separate from the cell therapy process. Vector quality can affect transduction efficiency, cell viability, vector copy number, potency, release outcomes, and comparability. Editing efficiency can affect product composition, safety testing, function, and batch profile.

Engineered immune cell manufacturing must connect the modification step to final cell function.

For example, a CAR-T program may need coordination between a lentiviral vector supplier, T-cell manufacturing site, flow cytometry lab, potency assay developer, sterility testing provider, cryogenic logistics team, and regulatory CMC consultant. A CAR-NK program may need donor-cell banking, feeder-free expansion, transduction optimization, cytotoxicity testing, post-thaw recovery evaluation, and allogeneic inventory planning.

Many CDMOs can support one part of this chain. CDMO Network can assemble the full chain around the product.

The product has to remain viable, identifiable, and biologically active after engineering.

iPSC-derived and stem cell therapy platforms

iPSC-derived and stem cell therapy programs require specialized control over source material, reprogramming history, differentiation, expansion, phenotype, potency, safety, and banking.

These products can include iPSC-derived immune cells, retinal cells, neural cells, cardiomyocytes, beta cells, MSC-like products, tissue-supportive cells, regenerative medicine programs, and other differentiated cell products.

The scientific history of iPSC technology is central to this part of the field. Shinya Yamanaka’s discovery that adult somatic cells could be reprogrammed into induced pluripotent stem cells in 2006 changed the direction of regenerative medicine and disease modeling. Human iPSC work also involved major academic contributions from Kyoto University and the University of Wisconsin-Madison, where researchers helped show that human somatic cells could be reprogrammed into iPSC lines.

CDMO Network supports these programs across cell source control, reprogramming support where relevant, banking, expansion, differentiation process development, phenotype testing, purity testing, residual undifferentiated cell testing where relevant, potency assays, cryopreservation, formulation, stability, and GMP readiness.

Stem cell and iPSC-derived products often carry complex comparability questions.

Small process changes can shift differentiation outcome, phenotype, potency, impurity profile, or safety-related attributes. A product can meet viability targets and still fail if the cell population does not show the right identity or function.

The manufacturing route must control the cell state, not only the cell count.

This is where the CDMO Network model is especially useful. An iPSC-derived therapy may need a reprogramming specialist, a differentiation process team, a GMP banking site, a residual pluripotency assay provider, a functional potency partner, cryogenic logistics support, and a regulatory CMC path for comparability. These capabilities rarely sit together inside one conventional CDMO.

MSCs, TILs, dendritic cells, and specialized cell therapies

Cell therapy includes many formats beyond CAR-T.

MSC programs require donor or source control, expansion, phenotype, potency, differentiation awareness, formulation, cryopreservation, and consistency. TIL programs require tumor material processing, cell expansion, phenotype, potency, sterility coordination, and patient-specific logistics. Dendritic cell therapies require cell sourcing, differentiation, antigen loading or activation, phenotype, potency, and clinical timing. Macrophage and myeloid cell therapies require specialized culture, activation state control, phenotype, and functional assays.

CDMO Network supports specialized cell therapy formats through process design, cell handling, expansion, activation, washing, harvest, formulation, QC testing, potency strategy, cryopreservation, and clinical logistics.

These programs cannot rely on generic immune-cell workflows.

Each cell type has its own biology, handling sensitivity, growth behavior, phenotype markers, potency logic, and release constraints. A macrophage product may depend on polarization and phagocytic function. A dendritic cell product may depend on antigen presentation and maturation state. A Treg product may depend on suppressive function. A gamma delta T-cell product may depend on expansion profile, cytotoxicity, receptor expression, and exhaustion markers.

A specialized cell therapy route must reflect the cell type rather than force the product into a standard template.

CDMO Network can support niche combinations such as:

• TIL expansion with patient-specific logistics, rapid sterility planning, and clinical-site coordination.
• Dendritic cell manufacturing with antigen-loading process support and phenotype panel development.
• Macrophage cell therapy support with activation-state analytics and functional assay design.
• MSC manufacturing with donor control, immunomodulatory potency strategy, and post-thaw functional testing.
• Gamma delta T-cell expansion with closed-system evaluation and cytotoxicity assay support.
• Treg process development with suppressive-function assay planning and release-method alignment.

These are not standard commodity workflows. They require cell-specific routing.

Potency, phenotype, and cell therapy analytics

Cell therapy analytics have to prove that the product is the intended cell population and that it performs the intended biological function.

Our support includes identity testing, viability testing, flow cytometry panels, phenotype testing, purity testing, potency assays, functional assays, cytokine release assays, killing assays, proliferation assays, differentiation assays, vector copy number support, transduction efficiency, editing efficiency, residual bead testing where relevant, residual vector testing where relevant, sterility coordination, mycoplasma testing, endotoxin testing, adventitious agent testing coordination, stability studies, and post-thaw performance testing. Potency is often the most difficult analytical area.

A CAR-T product may require cytotoxicity, activation, cytokine, or target-specific function. An NK product may require killing activity and phenotype. A Treg product may require suppressive function. An MSC product may require immunomodulatory or mechanism-related assays. An iPSC-derived product may require identity, differentiation state, purity, and functional readouts.

CDMO Network can connect manufacturing with the right analytical path early, instead of treating release testing as a late-stage add-on. That matters because weak assay strategy can slow tech transfer, comparability, clinical release, and regulatory review.

Cryopreservation, cold chain, and clinical handling

Cryopreservation can determine whether a cell therapy remains usable.

Cells can lose viability, potency, phenotype, or functional performance during freezing, storage, shipment, thawing, dilution, or administration preparation. Cryoprotectant selection, freezing rate, cell density, container format, storage temperature, thaw procedure, post-thaw hold time, and clinical-site handling all affect product quality.

CDMO Network supports cryopreservation strategy, formulation, controlled-rate freezing, cryobag or vial format review, post-thaw viability testing, post-thaw potency, shipping validation, chain-of-custody planning, chain-of-identity systems, temperature monitoring, excursion response, and clinical-site instructions.

Cold chain is not a shipping detail.

It is part of the product control strategy.

For autologous therapy, the logistics model must protect patient identity and timing. For allogeneic therapy, it must protect inventory, distribution, and consistent clinical use. For engineered cells, it must preserve the function created by the manufacturing process.

A cell therapy product has to survive the full path to administration.

GMP manufacturing, tech transfer, and scale-up

Cell therapy programs need manufacturing systems that match product type, stage, and treatment model.

CDMO Network supports non-GMP process feasibility, preclinical process development, GMP clinical manufacturing, autologous batch execution, allogeneic scale-up, closed-system manufacturing, multi-site transfer, method transfer, analytical transfer, commercial readiness, and lifecycle planning.

Our support includes process mapping, batch records, raw material control, media and reagent qualification, vector input coordination, equipment fit, closed-system evaluation, release testing, quality documentation, deviation handling, change control, comparability planning, and regulatory CMC support.

Scale-up and scale-out both matter.

Autologous programs often scale out through parallel patient-specific manufacturing. Allogeneic programs often scale up through larger expansion, banking, and batch-based production. Closed-system approaches can improve consistency, reduce contamination risk, and support operational scalability.

Tech transfer must preserve process knowledge, operator details, timing, cell-state sensitivities, assay logic, and cryopreservation conditions.

Cell therapy transfer is successful when the receiving site can reproduce the intended cell product, not simply repeat the steps.

細胞治療の製造では、細胞そのものが製品であり、機能単位でもあります 自家細胞治療、他家細胞治療、CAR-T、TCR-T、NK細胞、iPSC由来細胞、MSC、TIL、遺伝子改変細胞は、それぞれ異なる製造管理を必要とします CDMO Network は、細胞ソース、活性化、遺伝子導入、編集、増殖、洗浄、凍結保存、品質試験、力価評価、GMP製造、技術移転、コールドチェーン、臨床供給を製品の用途に合わせて接続します

Cell therapy niches supported

This modality group includes mainstream and highly specialized cell therapy formats.

Support extends across autologous cell therapy, allogeneic cell therapy, CAR-T, TCR-T, NK cell therapy, CAR-NK, iPSC therapy, iPSC-derived cell therapy, stem cell therapy, MSCs, dendritic cell therapy, macrophage cell therapy, HSC and hematopoietic cell therapy, tumor-infiltrating lymphocytes, TIL therapy, regulatory T cells, Treg therapy, gamma delta T cells, iNK cell therapy, gene-modified cell therapy, ex vivo cell engineering, genome-edited cell therapy, cell reprogramming, cell expansion, closed-system cell therapy manufacturing, point-of-care cell therapy manufacturing, and specialized engineered immune-cell platforms.

CDMO Network can also coordinate niche combinations that are hard to source through one traditional CDMO structure:

• iPSC-derived immune-cell manufacturing with genome editing, banking, and potency analytics.
• Autologous CAR-T manufacturing with rapid release, cryogenic logistics, and hospital thaw support.
• CAR-NK development with donor strategy, expansion, transduction, cytotoxicity assays, and inventory planning.
• TIL workflows with tumor processing, expansion, sterility coordination, and patient-specific delivery.
• MSC manufacturing with donor control, immunomodulatory potency, post-thaw testing, and distribution support.
• Engineered macrophage programs with vector coordination, activation-state control, and functional assays.
• Multi-site GMP transfer with harmonized analytics, chain-of-identity systems, and cold-chain validation.
• Point-of-care cell therapy models with closed-system workflows, local handling procedures, and quality oversight.

Each program receives a route based on cell type, starting material, modification method, intended mechanism, release strategy, potency logic, cryopreservation requirement, quality level, clinical model, and supply plan.

A single cell therapy manufacturing template cannot cover the field.

The cell type and treatment model define the route.

Top 17 FAQ – Cell Therapy Services

1. Why is CDMO Network the best partner for complex cell therapy programs?

CDMO Network combines specialized partners with cutting-edge niche equipment, closed-system platforms, and deep expertise across autologous, allogeneic, and advanced engineered cell therapies — delivering faster timelines, higher success rates, and solutions that single-site CDMOs simply cannot match.

2. What types of cell therapy programs does CDMO Network support?

We support autologous, allogeneic, CAR-T, NK-cell, TIL, iPSC-derived, stem cell, and genome-edited cell therapies — from early process development through GMP manufacturing and clinical supply.

3. How does your network model provide advantages over traditional CDMOs?

Our connected ecosystem of specialized facilities allows us to assemble the optimal manufacturing route for each program, offering multi-site flexibility, best-in-class equipment, and integrated capabilities that no single facility can provide.

4. Do you have experience with CAR-T and other engineered immune cell therapies?

Yes. We routinely support advanced CAR-T, NK-cell, and TCR programs with closed-system manufacturing, automated expansion, precise gene-editing integration, and robust vector coordination.

5. What makes your iPSC and stem cell manufacturing capabilities unique?

We utilize state-of-the-art iPSC differentiation platforms, proprietary bioreactor systems, and real-time process analytical technology (PAT) to deliver highly consistent, scalable, and clinically compliant iPSC-derived cell products.

6. How do you ensure GMP compliance and regulatory success?

Our partners operate under full GMP with extensive regulatory experience. We provide complete CMC documentation, risk-based validation, and proactive regulatory support to accelerate IND and BLA filings.

7. Can you handle both autologous and allogeneic programs?

Absolutely. We offer dedicated autologous workflows with rapid turnaround as well as large-scale allogeneic platforms designed for commercial scalability and cost efficiency.

8. What analytical capabilities do you offer for cell therapies?

We provide comprehensive advanced analytics including flow cytometry, potency assays, vector copy number, genomic integrity, sterility, endotoxin, identity, purity, and stability-indicating methods — all validated and phase-appropriate.

9. How do you protect cell viability during cryopreservation and cold chain?

Using optimized cryoprotectant formulations, controlled-rate freezing, vapor-phase liquid nitrogen storage, and validated shipping solutions, we maintain maximum post-thaw viability and potency.

10. Do you support decentralized or point-of-care manufacturing?

Yes. We help design and tech transfer closed, automated, decentralized manufacturing strategies tailored for hospital-based or regional production models.

11. What is your track record with tech transfer and scale-up?

We excel at seamless tech transfer with detailed comparability protocols, process characterization, and scale-up expertise — minimizing risk while accelerating programs from clinical to commercial.

12. How do you manage vector integration for gene-modified cell therapies?

We provide fully integrated viral vector coordination (AAV, lentiviral, etc.) with tight process controls, ensuring consistent transduction efficiency and product quality.

13. Can you support commercial-scale manufacturing?

Yes. Our network offers flexible commercial-ready capacity with both autologous batch and allogeneic large-scale platforms, supported by robust supply chain and quality systems.

14. What innovative technologies do you use?

We leverage automated closed systems, single-use bioreactors, real-time PAT, AI-driven process optimization, advanced genome editing tools, and next-generation cryopreservation platforms.

15. How do you reduce timelines from development to clinical supply?

Through parallel processing, pre-qualified platforms, integrated network coordination, and rapid tech transfer, we significantly compress development timelines while maintaining the highest quality standards.

16. What support do you offer for global or multi-regional clinical trials?

We provide multi-site manufacturing, international cold-chain logistics, global quality agreements, and localized regulatory expertise to support complex multi-country clinical programs.

17. Why should I choose CDMO Network for my cell therapy program?

CDMO Network offers the perfect combination of specialized niche equipment, scientific excellence, manufacturing flexibility, and a true partnership approach — helping cell therapy innovators move faster, reduce risk, and deliver transformative therapies to patients.

Do you need cell therapy CDMO support?

CDMO Network empowers cell therapy developers to advance complex programs seamlessly from process development through GMP manufacturing, analytical release, cryopreservation, and clinical supply — all within one coordinated network.

We provide comprehensive support for autologous, allogeneic, engineered immune-cell, stem cell, and iPSC-derived therapies, covering:

• Process design and optimization
• GMP manufacturing
• Advanced analytical characterization and release testing
• Vector integration and coordination
• Cryopreservation and cold-chain logistics
• Technology transfer and commercial readiness

By connecting specialized partners across the cell therapy ecosystem, CDMO Network delivers flexible, high-performance solutions that single-site CDMOs cannot match — including closed-system manufacturing, multi-site GMP operations, advanced genome-editing workflows, specialty analytics, cryogenic logistics, and integrated clinical supply strategies.

Whether your program involves CAR-T, NK-cell, TIL, iPSC differentiation, or decentralized manufacturing, we design a tailored pathway aligned with your therapy’s unique biology, dosing model, and commercial requirements.

Contact CDMO Network today to discuss how our integrated network can accelerate your cell therapy program from development to successful clinical and commercial supply!

Email our team at info@cdmonetwork.com